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Original article
Hypertension is more prevalent, more severe, and causes a 
disproportionate number of premature disabilities and deaths 
from myocardial infarction, stroke, and end-stage renal disease 
in African Americans than in any other racial/ethnic group in 
the United States.1–3 Evidence further shows that hyperten-
sion explains most of the racial disparity in mortality rates.4 
Accordingly, in order to close the health disparity gap, the care-
ful measurement and evaluation of blood pressure (BP) levels 
among African Americans is critical to (i) screen for hyperten-
sion and (ii) evaluate BP control among individuals treated for 
hypertension.
Clinic-based BP measurements may incorrectly diagnose 
a subset of individuals who present as having nonelevated 
BP in the clinic, but have elevated BP when measured within 
the context of their daily environment.5 Evidence suggests 
this phenomenon, referred to as masked hypertension, has 
important prognostic implications for a variety of health 
outcomes.6 Masked hypertensives are at a greater risk of tar-
get organ damage (TOD), cardiac dysfunction, and mortal-
ity compared to individuals with normotensive clinic and 
24-hour BP (i.e., sustained normotension), and have TOD 
and mortality rates comparable to individuals who present 
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BACKGROUND
The disproportionate rates of cardiovascular disease in African 
Americans may, in part, be due to suboptimal assessment of blood 
pressure (BP) with clinic BP measurements alone. To date, however, the 
prevalence of masked hypertension in African Americans has not been 
fully delineated. The purpose of this study was to evaluate masked 
hypertension prevalence in a large population-based sample of African 
Americans and examine its determinants and association with indices 
of target organ damage (TOD).
METHODS
Clinic and 24-hour ambulatory BP monitoring were conducted in 972 
African Americans enrolled in the Jackson Heart Study. Common carotid 
artery intima-media thickness, left ventricular mass index, and the uri-
nary albumin:creatinine excretion ratio were evaluated as indices of TOD.
RESULTS
Masked hypertension prevalence was 25.9% in the overall sam-
ple and 34.4% in participants with normal clinic BP. All indices of 
TOD were significantly higher in masked hypertensives compared 
to sustained normotensives and were similar between masked 
hypertensives and sustained hypertensives. Male gender, smok-
ing, diabetes, and antihypertensive medication use were inde-
pendent determinants of masked hypertension in multivariate 
analyses.
CONCLUSIONS
In this population-based cohort of African Americans, approximately 
one-third of participants with presumably normal clinic BP had masked 
hypertension when BP was assessed in their daily environment. Masked 
hypertension was accompanied by a greater degree of TOD in this 
cohort.
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as hypertensive both in the clinic and during 24-hour BP 
monitoring (i.e., sustained hypertension).6–10 Despite rec-
ognition of masked hypertension as a clinically important 
phenomenon, few studies have quantified the prevalence 
of masked hypertension in African Americans. If preva-
lence rates among African American populations are high, 
it could have tremendous implications for clinical practice, 
as it would suggest a large proportion of African Americans 
have undiagnosed or poorly controlled hypertension.
The purpose of this study was to evaluate the prevalence 
of masked hypertension in a population-based sample of 
African Americans who were enrolled in the Jackson Heart 
Study (JHS), the largest epidemiologic investigation of cardi-
ovascular disease (CVD) among African Americans to date. 
As secondary objectives, we examined the determinants 
of masked hypertension and evaluated its association with 
indices of TOD in this sample.
METHODS
Study population
The JHS is a large, single-site, population-based study of 
CVD among African Americans. Details of study design, 
recruitment, and data collection have been previously 
described.11–14 Briefly, 5,301 African American adults were 
recruited from the Jackson, Mississippi metropolitan area 
and underwent a baseline examination that consisted of 
interviewer and self-administered questionnaires and clini-
cal examinations that included BP measurements, urine and 
blood sampling, echocardiography, and carotid ultrasonog-
raphy all collected using standardized protocols. All partici-
pants were invited to participate in a 24-hour ambulatory 
BP monitoring (ABPM) session. In total, 1,144 (21.6%) par-
ticipants voluntarily underwent ABPM and were included 
in the present analyses. The JHS adhered to the guidelines 
set forth by the Declaration of Helsinki and was approved by 
institutional review boards of participating institutions. All 
participants provided informed consent.
Clinic BP
Clinic BP was measured using a Hawksley random-
zero sphygmomanometer (Hawksley and Sons Ltd.). 
Measurements were taken after a 5-minute silent rest in the 
right arm of seated participants whose back and arm were 
supported.15 Cuff size was determined by upper-arm cir-
cumference. The average of 2 measures taken 1-minute apart 
was used as the representative clinic BP.
Ambulatory BP monitoring
Participants underwent 24-hour ABPM using a noninva-
sive, portable BP monitor (Model 90207; SpaceLabs Medical, 
Rockville, MD) as previously described.11,16 A BP cuff was 
fitted to the participant’s nondominant arm with cuff size 
determined by upper-arm circumference. The device was 
programmed to obtain measurements at  20-minute inter-
vals throughout the 24-hour period. Prior to each ses-
sion, the monitor was calibrated against a Baum mercury 
sphygmomanometer (WA Baum, Copiaque, NY) using 3–5 
simultaneous ABPM and clinic BP readings.
Hypertension classifications
Clinic hypertension was defined as mean clinic BP 
≥140/90  mm Hg. Ambulatory hypertension was based on 
awake ABP and defined as mean BP ≥135/85  mm Hg in 
accordance with international guidelines.17,18 Hypertension 
subgroups were defined as follows: sustained normo-
tension was defined as having both normal clinic BP 
(<140/90 mm Hg) and awake ABP (<135/85 mm Hg); sus-
tained hypertension was defined as having both clinic hyper-
tension and ambulatory hypertension; masked hypertension 
was defined as having normal clinic BP and ambulatory 
hypertension; and white coat hypertension was defined as 
having clinic hypertension and normal awake ABP.
Echocardiography
Two-dimensional echocardiography was performed 
using the Sonos-4500 (Philips Medical Systems) ultrasound 
machine as previously described.11 Briefly, the imaging pro-
tocol consisted of a 30-minute examination from parasternal, 
apical, and subcostal windows. All 4 chambers were imaged 
for assessment of left ventricular (LV) dimensions and systolic 
function to allow for calculation of LV mass. LV mass was cal-
culated according to Devereux’s formula.19 LV mass index was 
calculated by dividing LV mass by estimated body surface area.
Carotid ultrasonography
Electrocardiography-gated, B-mode, and spectral steered 
Doppler with an integrated ultrasound machine was used to 
obtain carotid artery images.11 A detailed summary of ultra-
sonography methodology can be found in Supplementary 
Methods online. Briefly, mean and maximum values were 
obtained for each carotid artery segment, side, and wall. 
Recordings during maximum diastole (R wave) were used 
for analysis. Maximum likelihood estimates were calculated 
by adjusting for missing data in the collecting, processing, 
and reading of images. Common carotid artery intima-
media thickness represented a maximum likelihood esti-
mate of mean far-wall of average values across the right and 
left side of the common carotid artery.
24-Hour urine collection
All participants were invited to contribute a 24-hour urine 
sample during the baseline examination. Consenting partic-
ipants (n = 740) were given a 3-l jug and were instructed to 
collect a 24-hour urine sample by discarding the last voided 
urine before going to sleep and then collecting all voided 
urine up to and including the last void the following evening. 
Upon completion, urine samples were aliquoted and sent 
for analysis of albumin, creatinine, sodium, and potassium 
excretion.11 The urinary albumin:creatinine excretion ratio 
was quantified. Further details on 24-hour urine collection 
are provided in Supplementary Methods online.
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Covariates and additional variables
Age, gender, lifestyle behaviors (cigarette smoking, alcohol 
drinking, physical activity), and selected CVD risk factors 
(body mass index (BMI), diabetes, hypercholesterolemia, 
and high-sensitivity C-reactive protein) were included as 
standard covariates. Marital status, socioeconomic status 
(education, income), and lipids (total cholesterol, high- 
and low-density lipoproteins, triglycerides) were included 
to examine their relationship with masked hypertension. 
A detailed summary of methodology for these variables are 
reported in Supplementary Methods online.
Statistical analyses
Among the 1,144 participants who underwent 24-hour 
ABPM, analyses were restricted to participants with suc-
cessful ABPM (>75% of valid readings) and complete diary 
information. Supplementary Table  1 online shows the 
characteristics of JHS participants included (n  =  972) and 
excluded (n = 4,329) from current analyses.
The prevalence of masked hypertension was defined in 2 
ways: (i) prevalence among the overall sample; and (ii) preva-
lence among those with normal clinic BP (<140/90 mm Hg; 
n = 733). To examine the prevalence of masked hypertension 
with increasing clinic BP, participants were stratified into 5 
categories according to their clinic BP: (i) <100/70 mm Hg, 
(ii) 100–109/70–74 mm Hg, (iii) 110–119/75–79 mm Hg, (iv) 
120–129/80–84 mm Hg; and (v) 130–139/85–89 mm Hg. As 
some have contended that both awake and sleep BP be used to 
define masked hypertension,20 prevalence data were secondar-
ily quantified defining masked hypertension as either elevated 
awake (≥135/85 mm Hg) or sleep (≥120/70 mm Hg) ABP.
Participant characteristics were calculated by hyperten-
sion subgroup. Analysis of covariance was then used to eval-
uate differences in measures of TOD among hypertension 
subgroups after adjusting for age, gender, and BMI (model 
1). Subsequent progressive models additionally controlled 
for: current smoking, physical activity, and heavy alcohol 
drinking (model 2); and diabetes, hypercholesterolemia, 
and high-sensitivity C-reactive protein (model 3). Urinary 
albumin:creatinine excretion ratio values were left skewed 
and transformed using a natural logarithm to normalize the 
skewed distribution.
Logistic regression was used to identify factors that were 
associated with masked hypertension. For these analyses, the 
sample was restricted to individuals with normal clinic BP. 
Crude odds ratios were initially calculated. Subsequently, 
odds ratios were calculated with partial adjustment for age, 
gender, and BMI (model 1) and further adjustment for all 
variables significantly associated with masked hypertension 
in univariate analyses (model 2). Analyses were then repeated 
testing the following interactions: gender × BMI, gender × 
age, age × BMI, smoking × BMI, and age × antihypertensive 
medication treatment. The fit of the regression models were 
assessed by the Hosmer–Lemeshow goodness-of-fit test.
In order to compare with other population-based stud-
ies,21–23 primary analyses included participants both on 
and not on antihypertensive medication (e.g., treated and 
untreated). However, because masked hypertension among 
treated and untreated individuals underscores 2 separate 
issues (uncontrolled hypertension vs. undiagnosed hyper-
tension), as a sensitivity analysis, the above analyses were 
repeated separately for treated (n  =  565) and untreated 
(n  =  407) participants. Statistical analyses were performed 
using SPSS version 18.0 (SPSS, Chicago, IL).
RESULTS
Masked hypertension prevalence
The prevalence of masked hypertension was 25.9% in the 
overall sample and 34.4% among the 733 participants with nor-
mal clinic BP. When stratified by antihypertensive medication 
usage, masked hypertension prevalence among treated partici-
pants was 28.1% and 39.1% in the overall sample and in par-
ticipants with normal clinic BP, respectively. Among untreated 
participants, masked hypertension prevalence was 20.6% in the 
overall sample and 25.4% in participants with normal clinic BP.
Figure  1 shows the prevalence of masked hypertension 
across clinic BP categories. Masked hypertension prevalence 
increased with clinic BP levels, with individuals in the stage 
2 prehypertension range (130/85–139/89  mm Hg) having 
a prevalence of 51.4%. Similar trends were observed when 
Figure 1. Prevalence of masked hypertension by clinic blood pressure category in the Jackson Heart Study. 
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participants were stratified by antihypertensive medication 
use (Supplementary Figure 1 online).
The prevalence of masked hypertension when defined 
as either elevated awake or sleep ABP is presented in 
Supplementary Table 2 online.
Demographics and clinical characteristics by hypertension 
subgroup
Masked hypertensives were older, more likely to be male, 
more often current smokers, more likely to have diabetes, more 
often taking antihypertensive medications, had higher clinic 
systolic BP, and had higher ABP compared to sustained normo-
tensives (Table 1). There were no differences between masked 
hypertensives and sustained hypertensives with the exception 
of clinic and ambulatory BPs, which were lower in masked 
hypertensives. Similar trends were observed for participants on 
or not on antihypertensive medication (data not shown).
TOD by hypertension subgroup
Masked hypertensives had significantly greater common 
carotid artery intima-media thickness, LV mass index, and 










(n = 481) (n = 73) (n = 252) (n = 166) ANOVA
Age (years) 57.2 ± 11.4 60.9 ± 9.8* 60.4 ± 10.3** 60.9 ± 11.0** <0.001
Male (%) 26.4 26.0 34.5* 39.8**,† <0.01
Current smoker (%) 7.7 4.1 14.7**,† 13.9*,† <0.01
Heavy drinker (%) 24.2 18.1 29.2 23.9 0.22
Married (%) 52.3 54.8 54.8 55.4 0.87
Education (% ≤ HS) 37.0 30.1 35.3 39.2 0.58
Employment (% full-time) 40.3 35.6 36.9 36.1 0.66
Income level (% ≥ $50,000) 29.1 26.0 31.3 22.9 0.28
Postmenopausal (%) 88.2 91.8 88.2 93.4 0.47
Diabetes (%) 17.3 12.9 29.6***,†† 24.1 <0.001
Hypercholesterolemia (%) 32.0 33.3 36.5 30.5 0.59
Antihypertensive  
medication (%)
54.4 73.5** 69.1*** 69.7*** <0.001
Physical activity score 8.4 ± 2.6 8.1 ± 2.6 8.3 ± 2.6 8.1 ± 2.5 0.79
BMI (kg/m2) 31.5 ± 6.8 31.5 ± 7 30.6 ± 5.7 31.0 ± 6.3 0.44
Total cholesterol (mg/dl) 200.0 ± 39.4 209.2 ± 43.8 202.9 ± 40.5 201.8 ± 36.6 0.29
HDL cholesterol (mg/dl) 54.0 ± 14.7 54.8 ± 16.2 54.5 ± 14.8 54.1 ± 16.1 0.92
LDL cholestesrol (mg/dl) 124.9 ± 35.3 131.2 ± 38.1 127.4 ± 38.2 124.9 ± 33.4 0.51
Triglycerides (mg/dl) 106.3 ± 91.1 124.9 ± 81.4 104.8 ± 62.2 115.1 ± 74.6 0.08
hsCRP (mg/dl) 0.50 ± 0.72 0.51 ± 0.86 0.53 ± 0.87 0.48 ± 0.67 0.80
Sodium excretion (mEq/24 h) 157.1 ± 68.4 154.5 ± 72.8 163.7 ± 72.8 158.0 ± 69.4 0.82
Potassium excretion (mEq/24 h) 49.3 ± 33.8 47.6 ± 19.5 49.5 ± 23.0 51.1 ± 29.0 0.92
Clinic SBP (mm Hg) 117.8 ± 11.2 145.7 ± 16.7*** 124.5 ± 9.9***,††† 150.2 ± 14.6***,††,‡‡‡ <0.001
Clinic DBP (mm Hg) 73.7 ± 8.0 85.4 ± 10.2*** 75.1 ± 8.9††† 85.8 ± 11.1***,‡‡‡ <0.001
Clinic PP (mm Hg) 44.1 ± 10.4 60.4 ± 20.0*** 49.5 ± 10.6***,††† 64.4 ± 18.2***,†,‡‡‡ <0.001
Awake SBP (mm Hg) 121.5 ± 7.8 124.9 ± 6.4** 140.2 ± 9.4***,††† 146.2 ± 11.9***,†††,‡‡‡ <0.001
Awake DBP (mm Hg) 74.3 ± 6.2 74.2 ± 6.5 85.3 ± 8.0***,††† 87.6 ± 8.9***,†††,‡‡ <0.001
Sleep SBP (mm Hg) 113.3 ± 11 119.3 ± 11.7*** 130.7 ± 14.3***,††† 137.2 ± 15.7***,†††,‡‡‡ <0.001
Sleep DBP (mm Hg) 64.7 ± 8.0 66.2 ± 9.5 74.4 ± 11.1***,††† 76.6 ± 9.4***,†††,‡ <0.001
Data are presented as mean ± SD or percentage. 
Abbreviations: ANOVA, analysis of variance; BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HS, high school; 
hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; PP, pulse pressure; SBP, systolic blood pressure.
*P < 0.05, **P < 0.01, ***P < 0.001 vs. sustained normotension; †P < 0.05, ††P < 0.01, †††P < 0.001 vs. white coat hypertension; ‡P < 0.05, 
‡‡P < 0.01, ‡‡‡P < 0.001 vs. masked hypertension.
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urinary albumin:creatinine excretion ratio compared to sus-
tained normotensives in unadjusted and adjusted models 
(Table 2). Common carotid artery intima media thickness, 
LV mass index, and urinary albumin:creatinine excretion 
ratio were all similar between masked hypertensives and 
sustained hypertensives in unadjusted and adjusted mod-
els. The pattern of results were similar when subgroups were 
analyzed among participants on or not on antihypertensive 
medication (Supplementary Table 3 online).
Determinants of masked hypertension
In unadjusted models, age, gender, heavy drinking, smok-
ing, diabetes, antihypertensive medication, and clinic BP cat-
egory were associated with masked hypertension (Table 3). 
In multivariate-adjusted models, gender, smoking, diabe-
tes, antihypertensive medication, and clinic BP category 
remained significantly associated with masked hyperten-
sion. All interactions terms tested were not significant (P > 
0.05). Determinants of masked hypertension for treated and 
untreated participants are shown in Supplementary Tables 4 
and 5 online.
DISCUSSION
Despite the well-known racial disparities in CVD, few 
studies have quantified masked hypertension in all-Afri-
can American populations and none have done so among 
African Americans in the general population. In this com-
munity-based sample of African Americans there were sev-
eral important findings. First, we found that approximately 
one-third of JHS participants with seemingly normal clinic 
BP had masked hypertension. Second, a large proportion of 
masked hypertensives had stage 2 prehypertension. Third, 
male gender, smoking, diabetes antihypertensive medica-
tion use, and clinic BP were independent determinants of 
masked hypertension. Finally, the extent of TOD among 
masked hypertensives was higher than sustained normoten-
sives and resembled that of sustained hypertensives.
Heterogeneity among existing population-based stud-
ies makes it difficult to determine whether the prevalence 
observed in the JHS cohort might indicate that African 
Americans have a greater prevalence of masked hyperten-
sion compared to other race/ethnicities. Prevalence rates in 
other population-based studies were lower in comparison 
to the JHS cohort, ranging from 8% to 17% in the overall 
sample (vs. 26% in JHS) and 11%–23% among individu-
als with normal clinic BP (vs. 34% in JHS).21–24 In popula-
tion-based studies in Japan21 and Denmark,22 prevalence 
rates of masked hypertension (overall sample, treated, and 
untreated: 17%, 19%, and 16% in Japan; 12%, 10%, and 13% 
in Denmark) were lower in comparison to the JHS cohort 
when masked hypertension was defined using the same 
definition employed in the present study. Using this same 
definition, masked hypertension prevalence was also lower 
in the EPOGH project (12%),23 a population-based study of 










(n = 481) (n = 73) (n = 252) (n = 166) AN(C)OVA
CCIMT (mm)
 Unadjusted 0.70 ± 0.17 0.73 ± 0.18 0.78 ± 0.18***,† 0.81 ± 0.27***,†† <0.001
 Model 1 0.71 ± 0.01 0.71 ± 0.02 0.76 ± 0.01***,† 0.79 ± 0.01***,†† <0.001
 Model 2 0.71 ± 0.01 0.72 ± 0.02 0.76 ± 0.01** 0.78 ± 0.01***,†† <0.001
 Model 3 0.72 ± 0.01 0.72 ± 0.02 0.75 ± 0.01* 0.78 ± 0.02***,† <0.01
LVMI (g/m2)
 Unadjusted 74.3 ± 20.2 75.0 ± 20.9 85.6 ± 25.2***,††† 83.9 ± 25.2***,†† <0.001
 Model 1 75.3 ± 1.0 74.5 ± 2.6 84.8 ± 1.4***,†† 82.6 ± 1.7***,† <0.001
 Model 2 74.9 ± 1.0 74.3 ± 2.6 83.1 ± 1.5***,†† 81.2 ± 1.8**,† <0.001
 Model 3 75.4 ± 1.1 74.1 ± 2.7 82.1 ± 1.5***,†† 80.5 ± 1.8*,† <0.001
UACR (Log)
 Unadjusted 1.86 ± 0.92 2.07 ± 1.37 2.25 ± 1.32*** 2.48 ± 1.40***,† <0.001
 Model 1 1.86 ± 0.06 2.03 ± 0.15 2.27 ± 0.09*** 2.47 ± 0.10***,† <0.001
 Model 2 1.86 ± 0.06 1.97 ± 0.15 2.28 ± 0.09*** 2.45 ± 0.10***,†† <0.001
 Model 3 1.89 ± 0.06 2.03 ± 0.15 2.17 ± 0.09** 2.35 ± 0.10*** <0.001
Data are presented as mean ± SD (unadjusted analyses) or estimated marginal mean ± SE (adjusted analyses). Model 1 adjusts for age, 
gender, BMI. Model 2 adjusts for covariates in model 1 + current smoking status, physical activity score, and heavy alcohol drinking. Model 3 
adjusts for covariates in model 2 + diabetes status, hypercholesterolemia, and hsCRP. 
Abbreviations: ANCOVA, analysis of covariance; BMI, body mass index; CCIMT, common carotid artery intima-media thickness; hsCRP, high-
sensitivity C-reactive protein; LVMI, left ventricular mass index; UACR, urinary albumin creatinine ratio.
*P < 0.05, **P < 0.01, ***P < 0.001 vs. sustained normotension; †P < 0.05, ††P < 0.01, †††P < 0.001 vs. white coat hypertension.
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untreated adults from 7 European countries. The prevalence 
of masked hypertension in the PAMELA study, a popula-
tion-based study in Italy, was also lower (8%) when masked 
hypertension was defined by 24-hour ABP ≥125/79  mm 
Hg.24 Antihypertensive medication usage, however, was 
not reported, thus it is unclear how prevalence rates in the 
PAMELA study would compare when stratified according to 
antihypertensive medication treatment. From the reported 
prevalence rates in these studies it is apparent, although 
not strikingly, that African Americans in the JHS cohort 
have the highest prevalence rates among population-based 
studies published to date. Unfortunately, few studies have 
directly compared masked hypertension prevalence rates 
across racial/ethnic groups. Future studies in multiethnic 
samples in the United States may be warranted.
In previous studies that have reported on the prevalence 
of masked hypertension in all-African American popula-
tions, alarmingly high prevalence rates of 70% and 58% were 
reported among 691 African Americans with chronic kidney 
disease and among 58 putatively healthy African Americans 
with prehypertension, respectively.25,26 In the current study, 
masked hypertension prevalence among participants with 
normal clinic BP (34%) was considerably less. There are 2 
potential explanations for these differences. First, the chronic 
kidney disease and prehypertension inclusion criteria in the 
2 previous studies likely inflated masked hypertension prev-
alence. Second, masked hypertension prevalence is largely 
dependent on its definition, thus use of different ABP lim-
its undoubtedly will affect prevalence data. In the previous 
studies, masked hypertension was defined as either elevated 







POdds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Age (years) 1.03 (1.01–1.04) <0.001 1.03 (1.01–1.04) <0.001 1.01 (0.99–1.03) 0.13
Male gender 1.47 (1.06–2.04) 0.02 1.43 (1.02–2.00) 0.04 1.74 (1.18–2.56) <0.01
BMI (kg/m2) 0.98 (0.95–1.00) 0.08 0.98 (0.96–1.01) 0.23 - -
Current smoker (%) 2.07 (1.28–3.36) <0.01 2.36 (1.44–3.89) <0.01 1.93 (1.06–3.52) 0.03
Heavy drinker (%) 1.30 (0.91–1.84) 0.15 1.57 (1.08–2.27) 0.02 1.40 (0.91–2.16) 0.12
Married (%) 1.10 (0.81–1.50) 0.53 1.02 (0.74–1.41) 0.90 - -
Education (% ≤ HS) 0.93 (0.68–1.28) 0.66 0.78 (0.56–1.09) 0.15 - -
Employment (% full-time) 0.87 (0.63–1.19) 0.37 1.27 (0.87–1.87) 0.22 - -
Income level (% ≥ $50,000) 1.11 (0.80–1.55) 0.53 1.15 (0.82–1.62) 0.42 - -
Postmenopausal (%) 1.01 (0.55–1.84) 0.99 0.69 (0.35–1.33) 0.27 - -
Diabetes (%) 2.01 (1.34–2.90) <0.001 1.94 (1.33–2.83) <0.01 2.07 (1.35–3.18) <0.01
Hypercholesterolemia (%) 1.22 (0.88–1.71) 0.24 1.11 (0.78–1.56) 0.57 - -
Antihypertensive medication (%) 1.88 (1.34–2.63) <0.001 1.84 (1.27–2.66) <0.01 1.61 (1.07–2.43) 0.02
Physical activity score 1.00 (0.94–1.06) 0.88 1.03 (0.96–1.10) 0.41 - -
Total cholesterol (mg/dl) 1.00 (0.99–1.01) 0.38 1.00 (0.99–1.01)a 0.51 - -
HDL cholesterol (mg/dl) 1.00 (0.99–1.01) 0.65 1.00 (0.99–1.02) 0.57 - -
LDL cholesterol (mg/dl) 1.00 (0.99–1.01) 0.39 1.00 (1.00–1.01) 0.56 - -
Triglycerides (mg/dl) 1.00 (0.99–1.00) 0.82 1.00 (0.99–1.00) 0.83 - -
hsCRP (mg/dl) 1.04 (0.86–1.26) 0.69 1.10 (0.90–1.35) 0.36 - -
Sodium excretion (mEq/24 h) 1.00 (0.99–1.00) 0.30 1.00 (0.99–1.01) 0.19 - -
Potassium excretion (mEq/24 h) 1.00 (0.99–1.01) 0.93 1.00 (0.99–1.01) 0.79 - -
Clinic BP (mm Hg) - <0.001 - <0.001 - <0.001
 <100/70 ref - ref - ref -
 100–109/70–74 1.21 (0.36–4.04) 0.75 1.17 (0.34–3.94) 0.81 0.74 (0.20–2.70) 0.65
 110–119/75–79 1.42 (0.46–4.37) 0.55 1.28 (0.41–4.02) 0.67 1.04 (0.32–3.34) 0.95
 120–129/80–84 3.21 (1.07–9.60) 0.04 2.94 (0.97–8.93) 0.057 2.24 (0.71–7.01) 0.17
 130–139/85–89 5.82 (1.94–17.45) <0.01 5.52 (1.81–16.82) <0.01 4.21 (1.33–13.36) 0.02
Model 1: Adjusted for age, gender, and body mass index. Model 2: Adjusted for covariates in model 1 plus all variables significantly associ-
ated with masked hypertension in univariate analyses. 
Abbreviations: BP, blood pressure; CI, confidence interval; HDL, high-density lipoprotein; HS, high school; hsCRP, high-sensitivity C-reactive 
protein; LDL, low-density lipoprotein.
aHosmer–Lemeshow goodness-of-fit: P < 0.05.
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awake or sleep ABP. This is in contrast to the present study 
wherein masked hypertension was defined only by elevated 
awake ABP in accordance with international guidelines.17,18 
When we defined masked hypertension as either elevated 
awake or sleep ABP, masked hypertension prevalence among 
individuals with normal clinic BP approached that of previ-
ous studies (~55%).
Another important finding from our study was that 
masked hypertension prevalence was closely aligned with 
clinic BP. Whether ABPM should be introduced into clini-
cal practice to screen for masked hypertension is a matter 
of considerable debate. It is not feasible and may be inap-
propriate to do ABPM on all patients. From our findings, 
it could be argued that a more feasible scenario would be 
to screen African Americans who present as prehyperten-
sive. To narrow the focus more, JHS participants with stage 
2 prehypertension had a 4-fold higher likelihood of masked 
hypertension. More careful screening among African 
Americans in the prehypertensive range may be particu-
larly important as analysis of prehypertensives enrolled in 
the ARIC study showed a 3.29 higher risk of incident CVD 
among prehypertensive African Americans, most of whom 
were from Jackson, Mississippi, compared to normotensives, 
which exceeded previous findings from the Framingham 
Heart Study regarding the CVD risk conferred by prehyper-
tension.27,28 If ARIC participants had similar rates of masked 
hypertension as observed in the JHS cohort, this, in part, 
may explain the greater CVD risk among African Americans 
with prehypertension.
With respect to antihypertensive medication usage, the 
issue of masked hypertension in treated and untreated par-
ticipants is somewhat different as screening is not an issue 
in people who have already been identified as hypertensive. 
Instead the issue lies in the fact that normal clinic BP may 
give rise to the false impression that BP is adequately con-
trolled (e.g., masked uncontrolled hypertension). Previous 
work in the JHS has shown that control rates of hyperten-
sion among JHS participants were higher than in their 
African American counterparts from the National Health 
and Nutrition Examination Survey and similar to that of 
whites in National Health and Nutrition Examination 
Survey; leading investigators to speculate that hyperten-
sion control in African Americans may be better in the 
“stroke belt” compared with other parts of the country.15 
Although they reported that 66% of JHS participants with 
hypertension had controlled clinic BP, our findings suggest 
a number of those individuals had masked uncontrolled 
hypertensive (~39%). Notably, in the present analyses, 
treated participants had a 61% greater likelihood of hav-
ing masked hypertension. Considering the disproportion-
ate CVD burden in African Americans, these findings may 
further highlight the importance of assessing the control of 
hypertension outside of the clinic to help close the health 
disparity gap for African Americans.
The greater degree of TOD in masked hypertensives 
compared to sustained normotensives has been reported in 
many populations, and commonly, the degree of TOD has 
been reported to be similar to that of sustained hyperten-
sives.29 Our findings are in alignment with previous reports 
as indices of arterial, cardiac, and renal damage were all 
greater in masked hypertensives when compared to nor-
motensives, and were similar to that of sustained hyperten-
sives. These findings provide some of the first evidence that 
masked hypertension is associated with TOD in an African 
American population and could provide justification for 
the careful screening and diagnosis of hypertension in 
African Americans.
Several limitations must be noted when interpreting our 
findings. First, clinic BP measurements were obtained using 
a random-zero sphygmomanometer; a device that some 
studies have suggested may underestimate systolic and dias-
tolic BP.30 However, it has been reported that the underes-
timation of BP by this device are mainly due to observer 
variations in technique rather than intrinsic problems with 
equipment.31 Thus, it has been suggested that the underesti-
mation of BP by the random-zero sphygmomanometer can 
be minimized or eliminated when observer training is rig-
orous, technique is stringently monitored, and equipment 
is routinely maintenanced,31,32 such as that in the JHS.33 
Second, only 2 clinic BP measurements were taken at only 
one visit. This may have affected the reliability of masked 
hypertension classification. It should be noted, however, that 
masked hypertension reproducibility has been reported to 
be fair-to-moderate when defined using a single office BP 
average.34 Third, the JHS sample was designed to explore 
reasons for the racial disparity in hypertension and was not 
designed to function as a nationally representative sample. 
Thus, findings from the study might not be generalized to 
all African Americans. Fourth, the number of differences 
among included vs. excluded JHS participants for select 
demographic and clinical characteristics is reflective of a 
volunteer bias. Thus, our findings may also not be generaliz-
able to the entire JHS cohort. Finally, because of the cross-
sectional nature of our analyses, we cannot infer causality 
from the associations observed.
Despite these limitations, there are several strengths to 
our study. First, the JHS is the largest population-based 
study ever conducted among African Americans. This land-
mark study provided a unique and excellent opportunity to 
characterize in African Americans an important hyperten-
sion phenotype. Second, the subsample of JHS participants 
who conducted ABPM is one of the largest cohorts with 
ABPM in the United States. Finally, BP was measured by 
trained technicians using a standardized protocol that was 
stringently monitored.
In conclusion, in this population-based cohort of African 
Americans approximately one-third of participants with 
presumably normal clinic BP had undiagnosed or uncon-
trolled hypertension when assessed using ABPM. The 
prevalence of masked hypertension in this cohort from the 
JHS was higher than has been reported in other interna-
tional population-based studies; suggestive that African 
Americans may have a higher prevalence of masked hyper-
tension than other race/ethnicities. Future studies in mul-
tiethnic samples are needed to confirm this finding and 
determine whether more vigilant screening of BP in African 
Americans through out-of-office BP monitoring is war-
ranted to reduce racial disparities in CVD.
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